Lytix Biopharma is a clinical-stage company committed to developing novel immunotherapy for cancer patients. The aim is to become a leader within immunotherapy of solid tumors.

Lytix Biopharma’s development program focuses on immunological activation of solid tumors such as breast cancer, malignant melanoma, sarcoma, head & neck, and other. The mode of action is to release antigens and reshape the tumor microenvironment and as such turning cold tumors hot.

The strategy is to develop the oncolytic peptides within several tumor type indications, and also explore several therapeutic settings such as combination therapies and T-cell therapies.

For more information, please email us at: post@lytixbiopharma.com


Top 20 shareholders of Lytix Biopharma AS - as of 1 November 2017
Shareholder Number of shares % of shares +/- shares
last month
North Murray AS* 1 895 040 15.8  
Picasso Kapital AS 1 097 860 9.2  
TAJ Holding AS 970 810 8.1  
CARE Holding AS 750 930 6.3  
Norinnova Invest AS 451 160 3.8  
Lysnes Invest AS 406 750 3.4  
3 T PRODUKTER 352 680 2.9  
LMK Venture AB 346 000 2.9  
Hopen Invest AS 283 140 2.4  
Kreftforeningen 218 000 1.8  
Per Strand Eiendom AS 196 350 1.6  
Mikael Lönn 173 000 1.4  
Rothesay Limited 173 000 1.4  
4LB INVEST AS 160 040 1.3  
Norinnova Technology Transfer AS 155 790 1.3  
John Sigurd Svendsen 152 420 1.3  
Sparebank1 Nord-Norge Portefølje AS 151 820 1.3  
Jahatt AS 143 640 1.2  
Innovasjon Norge AS 133 790 1.1  
Øystein Rekdal* 118 630 1.0  
Other shareholders 3 202 620 26.8  
Total 11 957 500
100.0  

*Members of the board and/or management of Lytix Biopharma AS are represented.

 

Trades among insiders of Lytix Biopharma AS last month:
(I = Share issue, SO = Share Options)

 

* List of insiders within the Board and Management
Lytix Biopharma Board Lytix Biopharma Management
Gert Munthe, Chairman Edwin Klumper, CEO
Kari Grønås, member Håkan Wickholm, CBO
Lena Torlegård, member Øystein Rekdal, Co-founder and CSO
Morten Jurs, member Wenche Marie Olsen, COO
Debasish Roychowdhury, member Andrew Saunders, CMO
  Torbjørn Furuseth, CFO